Actelion Pharmaceuticals Ltd

Other

Idorsia Pharmaceuticals Ltd

Oliver Nayler

Claus Mueller

Boris Mathys

Martin Bolli

Beat Steiner

Michael Scherz

David Lehmann

Christoph Binkert

Jörg Velker

Cyrille Lescop

Thomas Weller

Martine Clozel

Daniel Bur

Jasper Dingemanse

Patrick Brossard

Hamed Aissaoui

Corinna Grisostomi

Lubos Remen

Magali Vercauteren

Keith Morrison

Richard Welford

Walter Fischli

Joerg Velker

J)org Velker

J&ouml;rg Velker

The present invention relates to a dosing regimen for a selective S1Preceptor agonist, whereby the selective S1Preceptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1Preceptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1Preceptor agonist.

Dosing regimen for a selective S1Pagonist

[object Object]

The present invention relates to compounds of the formula (I) wherein R, R, R, R, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase

The present invention relates to compounds of the formula (I) wherein R, R, R, R, R, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

Tricyclic piperidine compounds

The invention relates to compounds of the Formula (I), Formula (I) wherein Rand Rare as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. 

Pyridin-4-yl derivatives

The invention relates to pyridine derivatives of Formula (I) 

2-methoxy-pyridin-4-yl-derivatives

The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.

Thiazolidin-4-one-derivatives

Thiazolidin-4-one derivatives

Dosing regimen for a selective S1P1 receptor agonist

The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

Pyridine derivatives

The invention relates to pyridine derivatives of Formula (I), wherein A, R, R, R, and Rare as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. 

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims. 

Pyridine derivatives as S1P1/EDG1 receptor modulators

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists

The invention relates to pyridine derivatives of Formula (I) wherein A, R, R, R, R, R, and Rare as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. 

Pyridin-4-yl derivatives as immunomodulating agents

The invention relates to pyridine derivatives of Formula (I) wherein A, R, R, R, R, R, Rand Rare as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Growing community of inventors

Arlesheim, Switzerland

Oliver Nayler